Physiotherapy management of a rare variant of Guillain Barre Syndrome, acute motor and sensory axonal neuropathy (AMSAN) along with COVID-19 in a 35-year-old male—a case report

Surya Vishnuram, Kumaresan Abathsagayam, Prathap Suganthirababu

Abstract

Introduction: COVID-19 emerged as a novel pandemic with serious illness. Acute motor and sensory axonal neuropathy, a Guillain-Barré syndrome variant also results in ventilator support, and bed-ridden state. Presence of COVID-19 along with GBS will cause serious complications if left untreated.

Objective: To report the effect of physiotherapy in acute motor and sensory axonal neuropathy along with COVID-19 in Intensive care unit.

Case description: A 35-year-old-male with AMSAN, alcoholic hepatitis, and hyponatremia, came with paraparesis, ventilated due to poor oxygen saturation, diagnosed to have COVID-19, reduced muscle power in right wrist extensors, hand grip and diaphragm.

Method: 30 minutes physiotherapy session, thrice a day for a period of 4 weeks. The vital signs were taken as a primary outcome measure. Medical Research Council muscle power grading and Hughes functional grading scale were taken as secondary outcomes. All the outcome measures were assessed for 4 weeks.

Results: The 4 weeks of physiotherapy program show significant improvements on health status, muscle power, and functional status of an AMSAN patient with COVID 19.

Conclusion: From the results, it can be concluded that physiotherapy will be beneficial in AMSAN patients with COVID-19 in Intensive care units and further studies have to declare evidence-based practice.

Keywords: Acute motor-sensory axonal neuropathy; Intensive care unit; COVID-19; Gullian Barre syndrome.

DOI: https://dx.doi.org/10.4314/ahs.v22i3.56

Cite as: Vishnuram S, Abathsagayam K, Suganthirababu P. Physiotherapy management of a rare variant of Guillain Barre Syndrome, acute motor and sensory axonal neuropathy (AMSAN) along with COVID-19 in a 35-year-old male—a case report. Afri Health Sci. 2022;22(3): 520-526. https://dx.doi.org/10.4314/ahs.v22i3.56

Introduction

Guillain Barre syndrome (GBS) or Acute Inflammatory Demyelinating Polyneuropathy (AIDP), an autoimmune disorder that involves segmental demyelination and axonal damage following a viral infection; Both antibody and cell-mediated reactions to peripheral nerve myelin were involved and cause nerve cell death, thus regeneration doesn’t occur. About 2 per 100000 population per year experiences GBS, and 20% of them were reported to have variants such as Acute motor axonal neuropathy (AMAN), Acute motor and sensory axonal neuropathy (AMSAN) and Miller-Fisher syndrome.
about role of physiotherapy in GBS patients, there is no structured protocol for physical rehabilitation of AMSAN patient. There is a need of literature support to rehabilitate AMSAN patients diagnosed with COVID-19. The objective of this study is to report the effect of physiotherapy in a 35 years old male with AMSAN along with COVID-19 and to describe the progression in intensive care unit. Consequently, this study aims to investigate the effects of physiotherapy on vital signs, muscle power of key lower limb muscles, and functional status of an AMSAN patient with COVID-19.

Case description
A 35-years-old male with complaints of bilateral lower limb weakness, poor oxygen saturation, was bed-ridden with ventilator support. After the clinical examination and investigations, he was diagnosed to have hyponatremia, alcoholic hepatitis, and AMSAN variant of GBS along with features of paraparesis, reduced muscle power in right wrist extensors, hand grip, diaphragm weakness, and poor oxygen saturation. As a routine check-up during the pandemic, Asymptomatic COVID-19 positive report was documented at 2nd day of ICU stay and essential measures were taken. It is noted that 2 other patients in the same ward were also reported to be positive within last week, thus it is unclear that the source of transmission is external or internal. As per the treatment plan, he was isolated to COVID ICU, underwent IVIG in a dose of 2g/ kg of body weight during the initial 5 days of ICU stay and then, referred to the physiotherapy department for further management.

Subjective Assessment
The subjective assessment from the patient revealed that he was a chronic alcoholic came to the Emergency Department, SMCH, Chennai, India on November, 2020 with complaints of nausea, vomiting, abdominal pain, and lower limb weakness for 2 weeks. While, assessing the past medical history, the patient doesn’t possess any systemic or metabolic disorders and he was not under any medication. Based on his personal history, he was an alcoholic for past 3 years, non-smoker and he was a non-vegetarian. Travel history collected from the patient revealed a recent visit to a COVID suspected region nearby his town. His family history, socioeconomic history, and occupational history were unremarkable.

Objective examination
Vital signs were measured on each session before the therapy and after the therapy. The vital signs on the first day of therapy ranged between (Blood Pressure: 115-140/70-90 mmHg, Temperature: 96-98o F, Pulse Rate: 70-82/min, and SpO2: 96-100%, Respiratory Rate: 28-35/min, in pressure control mechanical ventilator with PEEP 6cmH2O, PIP 10cmH2O, FIO2 50%, and Ti 0.5 sec).

On observation
Mesomorphic, paradoxical pattern of respiration, patient was intubated with pressure control mechanical ventilator, presented with IV line on left metacarpal vein and urinary condom catheter. Both the lower limbs were extended, abducted, and externally rotated on supine lying. No significant edema, muscle wasting, or postural deformity was present.

Investigations and provisional diagnosis
The electrolyte report of the patient showed severe hyponatremia (122mEq/L). Grade 1 hepatosplenomegaly was diagnosed by USG abdomen/ pelvis. CSF analysis from lumbar puncture showed elevated protein levels and nerve conduction study resulted in reduced nerve conduction, thus the patient is diagnosed to be AMSAN variant of Guillain barre syndrome. Scrub typhus IgM was detected using IgM ELISA test. On testing the reverse transcription polymerase chain reaction (COVID-19 RT-PCR) at 2nd day of ICU admission, the result showed positive asymptomatic COVID-19 infection. The patient also underwent further diagnostic tests for differential diagnosis such as anti-HAV IgM/ anti-HEV IgM for hepatitis, CT-brain for higher centers involvement, and ABG analysis to determine acidity/alkalosis.

Physical Diagnosis
Bilateral lower limb weakness, right wrist extensor and hand grip weakness, hyporeflexia and hypotonia in both lower limbs, sensory disturbances at varied dermatomes, and diaphragm weakness as a result of AMSAN and COVID-19.

The short term goals were fixed to prevent bed rest/ pulmonary complications, improve muscle power in Lower limbs, right wrist extendors and hand grip, improve oxygen saturation, Enhance airway clearance, Facilitate muscle tone and proprioception in both Lower limbs, Im-
prove sitting balance, and long term goal was to train the patient as wheel chair independent.

Method

Outcome measures

The vital signs (heart rate, blood pressure, respiratory rate, and oxygen saturation)\(^ {10,11,12} \) were noted before and after the therapy, each day from baseline to 4 weeks follow-up as a primary outcome measure. (Table 1)

The Muscle power (flexors, extensors, and abductors of both the hips, flexors and extensors of both the knees, dorsi-flexors and plantar-flexors of both the ankles) were measured using Medical Research Council grading and tabulated in table 2. The MRC is a valid, consistent, and reliable tool\(^ {13,14} \), where the total scores range from 0 to 5 representing minimal performance and maximal performance, respectively.

The Hughes (GBS) disability score for functional status were measured from baseline to 4 weeks follow-up and tabulated in table 3. The Hughes disability score (GBSDS) is a reliable and valid assessment tool used to quantify the functional status of GBS patients\(^ {15} \). Both the MRC grading and GBSDS were taken as secondary outcome measures.

Interventions:

As the patient might experience fatigue, the physiotherapy program was broken down into 3 consecutive sessions with adequate rest intervals. Thus, the patient was treated for 30 minutes session thrice a day for a period of 4 weeks (a total of 90 mis per day and 5 days per week).

1st week

After framing the long-term goals, standard physiotherapy exercises\(^ {16,17} \) such as Muscle strengthening Exercises to upper limbs through manual resistance, assisted range of Motion Exercises for lower limbs in eliminated gravity position to retrain the muscles, passive range of motion exercises to lower limb joints and Deep vein thrombosis (DVT) prophylaxis to maintain joint range and peripheral circulation, joint compression to facilitate Tone and Proprioception, and positioning the patient to lateral or supine every 2 hours.\(^ {18,19,20} \) All the exercises were performed with regular rest intervals for the first 4 days of therapy. On the 5th day, as the patient was weaned off from ventilator and connected to 6 liters of oxygen support through oxygen face mask with 98% saturation, the patient was instructed to start incentive spirometry and breathing exercises from the 5th day and continued till the end of the week.

2nd week

As the vitals became stable in long sitting with 6 liters of oxygen support, the supply was reduced to 4 liters from the 2nd week and the patient is made to sit on the edge of bed with 2 person support for 10 to 20 minutes. Following, the improvement in static and dynamic balance in high sitting, after the 10th day, out of bed mobility to chair with 2 persons shift was started and the duration was progressed day by day from 10 minutes to 120 minutes. There was also improvement in right wrist extensor strength (MRC 2 to 3+) and lower limb muscles (MRC 2- to 2+). The upper limb strength training and assisted Range of Motion exercises to lower limbs in eliminated gravity position were continued with proper progressions in repetitions and sets as Endurance training. The remaining exercises were continued and the improvements in outcome measures were also documented.

3rd week

The RT-PCR after 14 days of admission was taken and the COVID-19 was significantly reduced in the patient's sample. Chair sitting duration increased day by day and the patient made to sit 2 hours at the end of second week. Independent bed mobility and reaching activities in sitting was also initiated from the third week. The patient's dynamic sitting balance improved in-between the third week, thus standing with 2 person support was also started while shifting the patient for 2 to 5 minutes. As the vitals became stable with 4 liters of oxygen support, the supply was reduced to 2 liters from the middle of the 3rd week. But the patient was unable to maintain oxygen saturation (<90%) within 2 hours, thus 4 liters supply was continued with 98% saturation.

4th week

Patient's endurance in lower limbs improved and achieved 30 reps in eliminated gravity position by the end of 3rd week and started manual resisted strength training to both lower limbs in eliminated gravity position. There was also improvement in lower limb muscles (MRC 2+ to 3-). As the patient's vital signs were stable, the patient was planned to shift from ICU to In-patient ward with 4 liters of oxygen supply and the physiotherapy exercises were continued focusing on muscle strength, mobility and functional independence.
Results
The vital signs were taken as the primary outcome measure, which shows gradual reduction to normal range in respiratory rate, blood pressure, heart rate, and requirement of oxygen support from baseline to end of 4 weeks (Table 1).

On comparing the lower limb muscle power (Table 2), it is well shown that muscle power of hip and knee muscles have improved; and reduction in GBS disability scale (Table 3) when compared from baseline to end of 4th week. From the results, it is proved that 4 weeks of physiotherapy program showed significant improvements on health status, muscle power, and functional status of an AMSAN patient with COVID 19.

Table 1. Vital signs of the AMSAN patient

| Vital signs       | Initial assessment | 1st week         | 2nd week         | 3rd week         | 4th week         |
|-------------------|--------------------|------------------|------------------|------------------|------------------|
| Heart rate        | 143/ min           | 120-130/min      | 100-110/min      | 70-100/min       | 70-90/min        |
| O₂ saturation     | 100% on ventilator | 95-100% on 6lits of O₂ | 91-95% on 4 lits of O₂ | 86-92% on 2 lits of O₂ | 92-96% on 4 lits of O₂ |
| Systolic Blood pressure | 134-140            | 125-135          | 126-130          | 113-120          | 115-130          |
| Diastolic Blood pressure | 82-90              | 74-90            | 72-84            | 76-81            | 72-76            |
| Respiratory rate  | 35/ min on ventilator | 24-28/ min on 6lits of O₂ | 25-30/ min on 4lits of O₂ | 28-32/ min on 2lits of O₂ | 22-25/min on 4lits of O₂ |
Table 2. Muscle power of the AMSAN patient

| Muscle power    | Initial assessment | 1st week | 2nd week | 3rd week | 4th week |
|-----------------|--------------------|----------|----------|----------|----------|
| Hip flexors     | 2-                 | 2-       | 2        | 2        | 2+       |
| Hip extensors   | 1+                 | 1+       | 2-       | 2-       | 2        |
| Hip abductors   | 2-                 | 2-       | 2        | 2        | 2+       |
| Knee flexors    | 1+                 | 2-       | 2        | 2        | 2        |
| Knee extensors  | 2-                 | 2-       | 2        | 2        | 2+       |
| Ankle Dorsiflexors | 0          | 0        | 0        | 0        | 0        |
| Ankle Plantarflexors | 0      | 0        | 0        | 0        | 0        |

Table 3. Functional status of the AMSAN patient

| Functional status | Initial assessment | 1st week | 2nd week | 3rd week | 4th week |
|-------------------|--------------------|----------|----------|----------|----------|
| GBS Disability scale | 5                | 4        | 4        | 4        | 4        |

Discussion
The present study aimed to report the effect of physiotherapy on vital signs, muscle power, and functional status of an AMSAN patient with COVID-19. Vital signs were used to assess the patient’s health status. The MRC grades were used to assess the muscle power, Hughes Disability scale assessed the functional status. Among various conservative managements, physiotherapy plays a major role in maximizing function and minimizing dysfunction in AMSAN patients.21, 22

The physical therapy program improved lower limb muscle power in this study similar to the previous study by Fisher et al.23 Besides, the results showed improved muscle power in lower limbs, improved static and dynamic balance in sitting, and functional status. Resistance training in this study achieved similar results among AMSAN patients, which has been previously reported by Markvardsen et al and Dimitrova et al.24, 25

However, COVID-19 appears to be uncommon with GBS26, few cases has been reported in previous studies and recommends COVID test for GBS patients27, 28 It was reported that COVID-19 will further reduce the functional ability of GBS patients.29 Thus, physiotherapy at early stages of COVID-19 management will facilitate recovery30 and it is also noted that the physical exercise along with the pharmacological treatment influenced the Blood pressure levels, Oxygen saturation, Respiratory rate, and pulse rate. Hence the active exercise program resembles aerobic exercise at a low intensity that is appropriate for the patient with AMSAN, unlike high-intensity muscle exercises.

Physiotherapy has a strong influence on respiratory functions, thus it is essential to restore the physical function effectively after AMSAN.30, 31 Although, physiotherapy has more beneficial effects on physical rehabilitation in AMSAN patients with COVID-19; the evidence of im-
plying physiotherapy as a standard protocol in clinical practice is lacking in research. Physiotherapy not only improve physical function in the studied AMSAN patient with COVID-19 but also provide airway clearance and maintain vital signs such as blood pressure, oxygen saturation, and respiratory rate as shown within the current study results.31 This single case study assessed the reliable and valid outcomes within the intensive care unit, it is also suggested that future follow-up studies in In-patient wards and out-patient clinics with large sample size will be beneficial to support the evidence-based practice.

Conclusion
Physiotherapy was found to effectively improve the muscle power and functional status in this AMSAN patient with COVID-19 and alcoholic hepatitis. Therefore, it can be concluded that physiotherapy will be beneficial in AMSAN patients with COVID-19 in Intensive care units and further studies have to declare evidence-based practice. However, low intensity relaxed exercises with tailored repetitions according to the patient’s physical ability can improve functional status and restore muscle strength for AMSAN and other neurological conditions.

Acknowledgement
Authors acknowledge the immense help received from the scholars whose articles are cited and included in references of this manuscript. The authors are also grateful to authors / editors / publishers of all those articles, journals and books from where the literature for this article has been reviewed and discussed.

Disclosure of Interest
The authors report no conflict of interest.

Source of funding
The author(s) received no specific funding for this work.

References
1. Berciano J, Sedano MJ, Pelayo-Negro AL, García A, Orizaola P, Gallardo E, Lafarga M, Berciano MT, Jacobs BC. Proximal nerve lesions in early Guillain–Barré syndrome: implications for pathogenesis and disease classification. Journal of neurology. 2017 Feb;264(2):221-36.
2. Ho, Tony. "Acute Motor and Sensory Axonal Neuropathy (AMSAN)." (2003): 36-39.
3. Leonhard SE, Mandarakas MR, Gondim FA, Bateman K, Ferreira ML, Corblath DR, van Doorn PA, Dourado ME, Hughes RA, Islam B, Kusunoki S. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nature Reviews Neurology. 2019 Nov;15(11):671-83.
4. Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: a case report. Journal of Clinical Neuroscience. 2020 Apr 15.
5. Nanda S, Handa R, Prasad A, et al. Covid-19 associated Guillain-Barre Syndrome: Contrasting tale of four patients from a tertiary care centre in India. Am J Emerg Med. 2020 Sep; 39:125-128.
6. Hughes RA, Swan AV, van Doorn PA. Cochrane Review: Intravenous immunoglobulin for Guillain-Barré syndrome. Evidence-Based Child Health: A Cochrane Review Journal. 2011 Jul;6(4):1176-231.
7. Gosselink R, Bott J, Johnson M, Dean E, Nava S, Norrenberg M, Schönhofer B, Stiller K, Van de Leur H, Vincent JL. Physiotherapy for adult patients with critical illness: recommendations of the European Respiratory Society and European Society of Intensive Care Medicine Task Force on physiotherapy for critically ill patients. Intensive care medicine. 2008 Jul 1;34(7):1188-99.
8. Nehal S, Manisha S. Role of physiotherapy in Guillain Barre Syndrome: A narrative review. Int J Heal. Sci. & Research: 5 (9): 529. 2015;540.
9. Pross G, Schlüeter M, inventors; HP Inc, assignee. Method and system for monitoring vital signs. United States patent US 5,343,869. 1994 Sep 6.
10. Ansar V, Valadi N. Guillain-Barré syndrome. Primary Care: Clinics in Office Practice. 2015 Jun 1;42(2):189-93.
11. Koeppen S, Kraywinkel K, Wessendorf TE, Ehrenfeld CE, Schürks M, Diener HC, Weimar C. Long-term outcome of Guillain-Barré syndrome. Neurocritical care. 2006 Dec 1;5(3):235.
12. John J. Grading of muscle power: comparison of MRC and analogue scales by physiotherapists. Medical Research Council. International journal of rehabilitation research. Internationale Zeitschrift fur Rehabilitationsforschung. Revue internationale de recherches de readaptation. 1984;7(2):173-81.
13. Vanpee G, Hermans G, Segers J, Gosselink R. Assessment of limb muscle strength in critically ill patients: a systematic review. Critical care medicine. 2014 Mar 1;42(3):701-11.
14. van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. A clinical progno-
tic scoring system for Guillain-Barré syndrome. The Lancet Neurology. 2007 Jul 1;6(7):589-94.
15. Simatos Arsenault N, Vincent PO, Yu BH, Bastien R, Sweeney A. Influence of exercise on patients with Guillain-Barré syndrome: a systematic review. Physiotherapy Canada. 2016;68(4):367-76.
16. Meythaler JM. Rehabilitation of Guillain-Barré syndrome. Archives of physical medicine and rehabilitation. 1997 Aug 1;78(8):872-9.
17. Clark KJ. Coping with Guillain-Barre syndrome (a personal experience). Intensive care nursing. 1985 Mar 1;1(1):13-8.
18. Fearnhead L, Fritz VU. Guillain-Barre syndrome-Rationale for physiotherapy management of the acute severe patient. South African Journal of Physiotherapy. 1996 Nov 30;52(4):85-7.
19. Karper WB. Effects of low-intensity aerobic exercise on one subject with chronic-relapsing Guillain-Barré syndrome. Rehabilitation Nursing Journal. 1991 Mar 1;16(2):96-8.
20. Davis D, Mendoza P. Rehabilitation of Patients with Peripheral Nerve Injuries. In Nerves and Nerve Injuries 2015 Jan 1 (pp. 783-804). Academic Press.
21. Davidson I, Wilson C, Walton T, Brissenden S. Physiotherapy and Guillain–Barré syndrome: results of a national survey. Physiotherapy. 2009 Sep 1;95(3):157-63.
22. Vispute AR, Kanase SB. Effect of Proximal Muscle Strengthening on Distal Muscle Facilitation in Guillain Barre Syndrome. Journal of Evolution of Medical and Dental Sciences. 2020 Sep 14;9(37):2741-6.
23. Fisher TB, Stevens JE. Rehabilitation of a marathon runner with Guillain-Barré syndrome. Journal of Neurologic Physical Therapy. 2008 Dec 1;32(4):203-9.
24. Markvardsen LH, Overgaard K, Heje K, Sindrup SH, Christiansen I, Vissing J, Andersen H. Resistance training and aerobic training improve muscle strength and aerobic capacity in chronic inflammatory demyelinating polyneuropathy. Muscle & Nerve. 2018 Jan;57(1):70-6.
25. Dimitrova A, Izov N, Maznev I, Grigorova-Petrova K, Lubenova D, Vasileva D. Physical therapy and functional motor recovery in patient with Guillain-Barré Syndrome-Case report. European Scientific Journal. 2017 Nov 30;13(33):11-9.
26. Caress JB, Castoro RJ, Simons Z, et al. COVID-19-associated Guillain-Barré syndrome: The early pandemic experience. Muscle Nerve. 2020;62(4):485-491.
27. Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: A case report. J Clin Neurosci. 2020;76:233-235.
28. Abdullahi A, Candan SA, Soysal Tomruk M, et al. Is Guillain-Barré Syndrome Associated With COVID-19 Infection? A Systemic Review of the Evidence. Front Neurol. 2021;11:566308.
29. Padroni M, Mastrangelo V, Asioli GM, Pavolucci L, Abu-Rumeileh S, Piscaglia MG, Querzani P, Callegarini C, Foschi M. Guillain-Barré syndrome following COVID-19: new infection, old complication?. Journal of neurology. 2020 Apr 24:1.
30. Jiandani MP, Agarwal B, Baxi G, Kale S, Pol T, Bhise A, Pandit U, Shetye JV, Divate A, Damke U, Ravindra S. Evidence-based National Consensus: Recommendations for Physiotherapy Management in COVID-19 in Acute Care Indian Setup. Indian Journal of Critical Care Medicine. Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine. 2020 Oct;24(10):905.
31. Thomas P, Baldwin C, Bisset B, Boden I, Gosselink R, Granger CL, Hodgson C, Jones AY, Kho ME, Moses R, Ntoumenopoulos G. Physiotherapy management for COVID-19 in the acute hospital setting: recommendations to guide clinical practice. Pneumon. 2020 Jan;33(1):32-5.